• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
  • Home
  • About Us
    • Our Vision, Mission and Values
    • How We Help
    • Our Trustees
    • Our Staff
    • Our Regional Parent Supporters
    • Our Professional Board
    • Newsletters
    • Annual Reports
  • News
    • News
    • SMS Family Events
    • Activities
    • Conferences
    • Research
    • Blog
    • Newsletters
  • Get Involved
    • Fundraising Events
    • Become a Member
    • Ways to Donate
    • Become a Regular Donor
    • Payroll Giving
    • Fundraising Ideas
  • Shop
    • Basket
  • Contact
  • Membership
  • Donate
Smith-Magenis Syndrome Foundation UK logo

Smith-Magenis Syndrome Foundation UK

Connecting Families, Raising Awareness, Building Futures

  • What is SMS?
    • Overview of SMS
    • New Diagnosis
    • A Guide to SMS Booklet
    • SMS Behaviours
    • Sleep in SMS
    • Living with SMS
    • Health
    • Facts about Smith-Magenis syndrome
    • Videos about SMS
    • Frequently asked questions
    • Find Support for SMS
  • Spotlight on SMS health
    • Vision
    • Sleep
  • Find Support for SMS
    • Small Grant Applications
    • Newlife’s Emergency Equipment Loan Service
    • Emergency hospital documents for download
    • Other Support Organisations
    • Scientific Papers
    • SMS Research
  • Our SMS Community
    • SMS Conference 2022
    • Become a Member
    • Regional Parent Supporters
    • Stories from our SMS Community
  • Home
  • About Us
    • Our Vision, Mission and Values
    • How We Help
    • Meet the Trustees
    • Meet the Staff
    • Regional Parent Supporters
    • Our professional board
    • Newsletters
    • Annual Reports
  • SMS Conference 2022
  • News
    • SMS Family Events
    • Activities
    • Conferences
    • Research
    • Blog
  • Get Involved
    • Events
    • Become a Member
    • Ways to Donate
    • Become a Regular Donor
    • Payroll Giving
    • Fundraising Ideas
    • Support My Smile Campaign
  • Shop
    • My Basket
  • What is SMS?
    • Overview of SMS?
    • New Diagnosis
    • SMS Behaviours
    • Living with SMS
    • Sleep and SMS
    • Health
    • Facts about Smith-Magenis syndrome
    • Frequently asked questions
    • Find Support for SMS
  • Spotlight on SMS health
    • Vision
    • Sleep
  • Find Support for SMS
    • Small Grant Applications
    • Newlife’s Emergency Equipment Loan Service
    • Emergency hospital documents for download
    • Other Support Organisations
    • Scientific Papers
    • SMS Research
    • Videos
  • Our SMS Community
    • Become a Member
    • Regional Parent Supporters
    • Stories from our SMS Community
  • Contact

Melatonin Application Rejected by SMC

September 13, 2019
Graph showing sleep patterns in SMS

The Scottish Medicines Consortium (SMC) has rejected the application to recommend prolonged-release melatonin (Slenyto®) as a treatment for insomnia in children with autism spectrum disorder and/or Smith-Magenis syndrome (SMS). The decision was based on uncertainty that this medicine would offer value for money to NHS Scotland. The wider implication is that the SMC are saying that prolonged-release melatonin should not normally be prescribed on the NHS in Scotland for the treatment of insomnia in children with Smith-Magenis syndrome and that other treatment options should be explored instead. Prescriptions can be specially requested by the healthcare professional on an individual basis. The Smith-Magenis Syndrome (SMS) Foundation UK will continue to support families and medical practitioners with over 20 years of scientific and clinical evidence to justify the use of modified-release melatonin for those with this rare genetic disorder.

The child with Smith-Magenis syndrome has a different sleeping pattern to the rest of their family and community. Whilst they do not themselves have a sleep problem, their sleep profile creates challenges for others and their own safety. Their activity whilst others are sleeping can increase the risk of serious incidents for both the child (including through self-injury) and their family. Night time wake periods also disrupt the sleep of other members of the household. Reducing the negative impact of night waking on family sleep may also increase caregivers’ capacity to most effectively support children with the syndrome which is eroded through chronic sleep disturbance.

Sleep problems are highly characteristic of people with SMS, more so than of other people with an intellectual disability including autism (where sleep problems are also elevated). Sleep is a significant problem for 88% (#1) people with the syndrome, and that this is likely to have a biological cause in most people; SMS is characterised with an inverted circadian rhythm as shown in the graph (#2), promoting daytime sleeping and night-time waking. Sleep disturbance is evident both in people with SMS caused by a deletion and people with SMS caused by the mutation of RAI1.

Graph showing sleep patterns in SMS

Severe night waking is experienced by 80.8% of those with SMS, with 73.1% having severe early morning waking. Settling for sleep is not a significant problem (#3).

With inverted melatonin release as the primary cause of sleep disorder in SMS, then treatment providing evening modified-release melatonin and/or suppressing its daytime release (e.g. using beta-blockers) might be expected to be effective (#4). As well as improving night-time sleeping, normalising the circadian rhythm provides more opportunities for the family to engage in daytime activities improving overall quality of life. Parents and carers would be less tired with improved work prospects.

The Smith-Magenis Syndrome (SMS) Foundation UK is naturally disappointed at the decision from the Scottish Medicines Consortium. We will continue to raise awareness of the syndrome and encourage the adoption of interventions determined by the SMS researchers and clinical practitioners. We also recognise the extra stress this decision places on parents and carers in seeking medicines that have been suggested by the experts in Smith-Magenis syndrome, and we will continue to support families with the information and guidance needed for positive outcomes.

Slenyto® has been recommended by National Institute of Health and Care Excellence (NICE) for use in England. The All Wales Medicine Strategy Group is to review the application for Wales in November 2019.

https://www.scottishmedicines.org.uk/medicines-advice/melatonin-slenyto-full-smc2168/


References:

(#1) Gender, genotype, and phenotype differences in Smith–Magenis syndrome: a meta-analysis of 105 cases.
Edelman, E. A., Girirajan, S., Finucane, B., Patel, P. I., Lupski, J. R., Smith, A. C. M., & Elsea, S. H. (2007).
Clinical genetics, 71(6), 540-550.

(#2) Inversion of the circadian rhythm of melatonin in the Smith-Magenis syndrome.
De Leersnyder, H., de Blois, M. C., Claustrat, B., Romana, S., Albrecht, U., von Kleist-Retzow, J. C., … & Munnich, A. (2001).
The Journal of paediatrics, 139(1), 111-116.

(#3) A cross-syndrome cohort comparison of sleep disturbance in children with Smith-Magenis syndrome (SMS), Angelman syndrome (AS), autism spectrum disorder (ASD) and tuberous sclerosis complex (TSC).
Trickett et al (2018).
Journal of Neurodevelopmental Disorders (2018) 10:9.

(#4) Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment.
De Leersnyder, H.
Trends Endocrinol Metab. 2006 Sep;17(7):291-8. Epub 2006 Aug 4.

Share:

Share on Facebook Share on Twitter Share on LinkedIn Share on E-mail
Category: News, Research

Like this article?

Sign-up with your email address below and we’ll keep in touch, sending you our latest news and articles about Smith-Magenis syndrome.

Previous Post: « Prof Chris Oliver presenting at the 2017 SMS Conference Outline 2019 Conference Schedule
Next Post: Our 2020 Vision changing charity structure image »

Join our Community

Join as a family member and we can connect you with families living near you. You will also receive updates of any social meetings, conferences, and fundraising events going on! Joining is quick and easy!

Join
View the international map of families diagnosed with SMS

Never feel isolated or alone.
Call our helpline: 0300 101 0034
Other ways to Contact Us

Please note: This is an answerphone service that will alert us as soon as a message is left. A trustee will call you back as soon as possible – we aim to respond to messages within 24 hours.

  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • YouTube
  • Mail

The Smith-Magenis Syndrome (SMS) Foundation UK CIO

Connecting Families, Raising Awareness, Building Futures

Sign-up to receive the latest news and information direct to your inbox

Please enter your email address below if you would like us to send you emails with our latest news, articles, and information about SMS.
To join as a full member, please click here.
Your data will be processed in accordance with our privacy notice.

Proud finalist of Keele University Breaking the Mould awards
SCA Terrific trustee award 2020
NUE Best Student contribution

Registered UK Charity (CIO) 1186647   ·  Scottish Charity (SCIO) SC050921    

Copyright © 2021 Smith-Magenis Syndrome (SMS) Foundation UK CIO · Privacy Policy · SMS Disclaimer · Terms and Conditions